Antiphospholipid syndrome and Trousseau's syndrome

Uchiyama, Shinichiro; Terashi, Hiromi; Shimizu, Yuko; Hashimoto, Shiori; Iwata, Makoto

doi:10.3995/jstroke.27.547

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trousseau syndrome is a paraneoplastic syndrome that produces neurological symptoms associated with latent malignant tumors. This condition is recognized to cause systemic thrombosis as well as brain infarction due to enhancement of the coagulant system induced by the malignant tumor (Uchiyama, Terashi, Shimizu, Hashimoto, & Iwata, 2005). Mucin‐producing adenocarcinoma is a frequent histologic type in such cases (Sutherland, Weitz, & Liebman, 2003; Umehara, Nomoto, & Yanazume, 2006).…”

Section: Discussionmentioning

confidence: 99%

Trousseau syndrome with intrahepatic cholangiocarcinoma that could be removed radically after endovascular treatment: Report of a case

et al. 2020

View full text Add to dashboard Cite

Background Trousseau syndrome is a poor prognosis. We report a case of Trousseau syndrome treated by radical resection after endovascular treatment. Case A 59‐year‐old woman presented to our department reporting spontaneous dizziness and pain of the upper abdomen. Magnetic resolution imaging (MRI) showed shower embolization of Brain. Contrast‐enhanced computer tomography (CT) showed renal infarction and splenic infarction, and a tumor was observed in the retrohepatic area. On day 9, sudden right side joint prejudice, neglect of left half space, and left hemiplegia were observed. MRI revealed obstruction of the right middle cerebral artery (MCA) perfusion zone. On the same day, endovascular treatment was performed and reperfusion was obtained. We decided on a radical surgery policy because there were a primary lesion and a high risk of new embolism, and no metastasis was seen. Discussion Trousseau syndrome generally has a poor prognosis, but active treatment should be considered as an option when we can expect the recovery of function.

show abstract

Section: Discussionmentioning

confidence: 99%

Trousseau syndrome with intrahepatic cholangiocarcinoma that could be removed radically after endovascular treatment: Report of a case

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Trousseau syndrome is a paraneoplastic syndrome that produces neurological symptoms associated with latent malignant tumors. This condition is recognized to cause systemic thrombosis as well as brain infarction due to enhancement of the coagulant system induced by the malignant tumor [2] and has been reported in connection with gastric, lung, pancreatic and ovarian cancers. Mucin-producing adenocarcinoma is a frequent histologic type in such cases [3,4] , and 1–25% of cancer patients have been shown to have phlebothrombosis depending on the primary site (histologic type) [5] , stage of disease and cycle of treatment.…”

Section: Discussionmentioning

confidence: 99%

“…As a coagulation mechanism activated by malignant tumors, the tumor cells produce tissue factor, tumor pro-coagulants and cellularity coagulants, such as factor V receptors and fibrinolysis proteins, as well as fibrinolysis inhibitor, which activate the coagulation cascade. The activation of coagulation is promoted by interactions between blood platelets, monocytes and endothelial cells via the actions of various cytokines and tumor antigens, with consequent immune complex thrombogenesis [2] .…”

Section: Discussionmentioning

confidence: 99%

“…Since then, various reports have assessed the characteristics of whole body thrombosis as a form of paraneoplastic syndrome. Trousseau syndrome has a poor prognosis, and it is very difficult to control the thrombosis; however, it is unknown whether controlling the cancer, which is the original illness, can be used to control the thrombosis [2] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy

Masubuchi

Maeno

Uchida

et al. 2015

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

A 47-year-old female with no history of previous illnesses developed cerebral infarction and was diagnosed with lung cancer, specifically EGFR mutation-positive adenocarcinoma, and Trousseau syndrome.The patient's response to anticoagulant therapy with non-fractionated heparin was very poor; however we were able to control the thrombosis with chemotherapy. She survived for one year and 10 months following treatment with gefitinib, CBDCA + PEM and erlotinib, without recurrence of thrombosis.Trousseau syndrome carries a poor prognosis and controlling thrombosis is difficult. In this case, the administration of anticancer therapy allowed use to control the patient's thrombosis. Therefore, this case highlights the importance of treating cancer in patients with Trousseau syndrome. In addition, the FDP and D-dimer levels changed in parallel with changes in the CEA level, which suggests that the activity of cancer is related to an internal thrombotic tendency. Hence, changes in the FDP and D-dimer values are associated with the efficacy of treatment with EGFR tyrosine kinase inhibitors and chemotherapy and may function as markers of recurrence.

show abstract

Development of Trousseau syndrome in a patient awaiting surgery for a pancreatic body tumor: A case report

Kikui¹,

Sawa²,

Nishiwaki³

2011

Jpn. J. Stroke

View full text Add to dashboard Cite

Antiphospholipid syndrome and Trousseau's syndrome

Cited by 7 publications

References 0 publications

Trousseau syndrome with intrahepatic cholangiocarcinoma that could be removed radically after endovascular treatment: Report of a case

Trousseau syndrome with intrahepatic cholangiocarcinoma that could be removed radically after endovascular treatment: Report of a case

A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy

Development of Trousseau syndrome in a patient awaiting surgery for a pancreatic body tumor: A case report

Contact Info

Product

Resources

About